The Endocrine Society and various endorsing organizations recently published recommendations for improving and standardizing testosterone testing.
Toward Excellence in Testosterone Testing: A Consensus Statement” asserts that urologists and other health-care providers must understand the importance of using accurately calibrated testosterone tests—a process that the groups hope to have fully in place in 2012 (J Clin Endocrinol Metab. 2010;95:4542-4548; available here, accessed November 12, 2010 ).
Endocrinologist William Rosner, MD—professor of medicine at Columbia University in New York, and a lead author of the consensus statement—explains to Renal & Urology News what impending testosterone-testing standardization—and the current lack of it—means to urology practice and research.
The American Urological Association has endorsed your consensus statement. Has the lack of standardization in testosterone testing been a long-recognized problem in the urology community as well as in the endocrinology community?
Dr. Rosner: There is a subset of urologists who are familiar with this issue, but it has been a long-recognized problem in the endocrine community.
But will you need some kind of buy-in from the wider urology community?
Dr. Rosner: Yes. We need some kind of buy-in from everybody: from physicians, from insurance payers, from the NIH [National Institutes of Health], from medical journals.. Everybody has to insist that this be done properly. That’s why they were invited to the [February 2010] conference [convened to help formulate the consensus statement].
How would that work?
Dr. Rosner: Journals would have to insist that any papers they accept have numbers generated from acceptable methods. And for NIH-funded studies, the NIH would have to agree that it’s more expensive to pay for improper determinations in the long run and allow budgets that may cost a bit more but provide reliable results. In the short run, standardization looks more expensive.
But in the long run, it’s less expensive because you don’t have to repeat tests a million times; you don’t give patients the wrong medicine and run into complications because you’re dealing with wrong numbers. So, insurers should also insist on standardization because it’s expensive in the long run to go with the wrong numbers. It’s also the only way to get useful evidence-based guidelines.
So this issue has been brewing for a long time?
Dr. Rosner: Yes. It’s been brewing for about eight to nine years, I would say. There’s been an enormous amount of inertia while trying to get this done. A lot of it is financial, but it’s also a matter of simplicity. A platform assay takes the blood sample and quickly yields 40 answers—that’s a quick turnaround time and it’s relatively inexpensive. It happens to give you the wrong answer in the case of testosterone testing, but we have opted for simplicity and lower costs over accuracy. Money and inertia are always the biggest pitfalls.
You’re saying that testosterone testing as part of that platform assay does not yield accurate results?
Dr. Rosner: That is correct. Immunoassay-based platform assays are demonstrably inaccurate, especially at the low end, where the patient population that needs treatment resides—e.g., hypogonadal men and normal women or, more accurately, women with androgen-based disorders.
How will standardization change the way urologists practice?
Dr. Rosner: There’s a big unknown area about when to replace testosterone, especially in the aging man. It’s easy if men have really low testosterone, but in the borderline area—say between 200-300 ng/dl—you need an accurate assay to know who needs replacement. Of course, we don’t replace testosterone on the numbers alone; we replace it based on the combination of symptoms and blood tests. Because values for testosterone in this borderline region are very often measured inaccurately by most current methods, we are faced the very real possibility of under- or overtreating.
How does the plan look cost-wise?
Dr. Rosner: We don’t know yet; we’re not married to a method but rather to ensuring that all tests can be traced back to single agreed upon standard. The standardization part should not be too costly. The cost of using methods that match the standard is in evolution. We should have a better idea of costs in a year or so.
The trouble is that there has been no universally agreed upon testosterone standard. However, a standard now has been established by the CDC [Centers for Disease Control and Prevention], and individual laboratories can subscribe to the [CDC’s] program, a quality control program that will ensure accuracy. Now that we have a standard, we have to insist that everybody adhere to it. We’re looking for compliance with the standard, not with any particular method of testing.
Has an effort like this ever been launched?
Dr. Rosner: For testosterone it’s a first, but the same thing was done with cholesterol. Initially, there was no standardization. The CDC led the way on that. Think about it – how could one promulgate guidelines for cholesterol in blood if different labs and methods gave widely differing results on the same sample. The same situation existed with hemoglobin A1c; we had guidelines, but everybody was getting different answers from their tests— so the guidelines weren’t meaningful. Now the guidelines have meaning because the tests are traceable to a single standard.